Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Genomic Urine Testing Market Revenue Growth Supported By A CAGR Of 1.79% Through 2030

The market for genomic urine testing has experienced significant expansion lately. Projections indicate it will rise from a valuation of $1.01 billion in 2025 to $1.13 billion in 2026, reflecting a compound annual growth rate of 12.5%. Factors contributing to this historical growth trajectory include breakthroughs in molecular diagnostic technologies, an increasing demand for less invasive testing methods, pioneering research into early biomarkers, the wider integration of genomic assays by laboratories, and the overall expansion of the oncology diagnostics sector.

The market for genomic urine testing is projected for substantial expansion in the coming years, anticipating a rise to $1.8 billion by 2030, driven by a compound annual growth rate of 12.2%. This growth trajectory is expected to be fueled by several key factors, including its incorporation into standard health check-ups, its broadened application in identifying infectious diseases, advancements in testing sensitivity, a growing need for individualized health monitoring, and ongoing clinical validation research. Furthermore, significant market shifts anticipated during this period involve a greater acceptance of diagnostic methods that do not require invasive procedures, an increased reliance on genomic markers for pinpointing diseases, a higher demand for early-stage cancer detection instruments, the wider implementation of tailored diagnostic strategies, and intensified investigations into the profiling of urinary genomics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

Genomic Urine Testing Market Growth Momentum: Which Factors Are Influencing Demand?

The escalating challenge posed by chronic kidney disease is poised to fuel the expansion of the genomic urine testing market. This persistent condition, characterized by compromised kidney function and an inability to adequately cleanse the bloodstream, results in the accumulation of toxins and excess fluid. The growing prevalence of diabetes, a major contributor to this increase, exacerbates kidney damage as elevated glucose levels harm the delicate blood vessels within the kidneys, thereby hindering their filtering capacity. Genomic urine testing plays a crucial role in managing chronic kidney disease by facilitating the early identification of specific genetic indicators, which in turn enables prompt therapeutic actions and tailored management strategies. This leads to improved patient results through enhanced diagnostic precision and a mitigation of the disease’s advancement. Illustratively, based on a report from The American Journal of Managed Care in November 2025, an estimated 788 million adults in the United States, aged 20 and above, were identified as having CKD in the year 2023. Consequently, the expanding impact of chronic kidney disease serves as a significant impetus for the growth of the genomic urine testing sector.

Genomic Urine Testing Market Segment Analysis And Revenue Opportunities

The genomic urine testing market covered in this report is segmented –

1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

Genomic Urine Testing Market Trends Reshaping Industry Growth

In the realm of genomic urine testing, key players are concentrating on forging pioneering approaches, including the implementation of next-generation sequencing (NGS), to elevate the precision, responsiveness, and early identification potential of non-invasive diagnostic methodologies for a spectrum of ailments. This sophisticated DNA sequencing technology, NGS, facilitates swift, precise, and extensive examination of genetic components by concurrently sequencing vast quantities of DNA segments. As an illustration, consider the introduction in May of 2023 by Convergent Genomics Inc., a biotechnology firm headquartered in the United States, of their genomic urine assay, UroAmp. Employing next-generation DNA sequencing, this test scrutinizes alterations in 60 genes linked to bladder cancer, thereby facilitating its early detection, potentially up to a dozen years prior to the manifestation of clinical signs. The assay furnishes comprehensive genetic intelligence to inform diagnostic processes, therapeutic choices, and the surveillance of disease recurrence, presenting a greater degree of accuracy compared to established techniques such as cytology and cystoscopy.

Genomic Urine Testing Market Leading Players Shaping Industry Direction

Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

Access The Complete Genomic Urine Testing Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

Genomic Urine Testing Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the genomic urine testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model